Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System

Table 1 Targeted therapy agents that can be prescribed by national insurance in Korea for the treatment of metastatic kidney cancer

Agent	Brand name	National insurance coverage year in Korea	Pathway	Dosing phase	Dosing therapy
Sunitinib	Sutene®	2007	TKI	First or more	P, S
Sorafenib	Nexavar	2007	TKI	First or more	P, S
Pazopanib	Votrient	2011	TKI	First or more	P, S
Everolimus	Afinitor	2011	mTOR inhibitor	Second or more	S
Axitinib	Inlyta	2018	TKI	Second	S
Cabozantinib	Cabometyx	2019	TKI	Second or more	S

TKI Tyrosine Kinase Inhibitor, mTOR mammalian target of rapamycin, P palliative, S salvage

ISSN: 1471-2407